ArticleBMC cardiovascular disorders2026
Effects of evolocumab combined with statin therapy on blood lipids, inflammatory factors, and endothelial function in patients with coronary heart disease.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCoronary heart disease (CHD) remained a leading cause of morbidity and mortality, necessitating innovative treatment strategies. This study aimed to evaluate the efficacy and safety of evolocumab combined with atorvastatin compared to atorvastatin monotherapy in patients with CHD.
methodsThis retrospective cohort study included CHD patients admitted between February 2023 and April 2024. Patients were divided into two groups: the Monotherapy Group received atorvastatin alone (75 patients) and the Combination Therapy Group received both evolocumab and atorvastatin (76 patients) for a duration of three months. Lipid profiles, inflammatory markers, and endothelial function parameters were assessed before and after treatment completion.
resultsIn the Combination Therapy Group, significant improvements were observed in total cholesterol (2.65 ± 0.77 mmol/L vs. 2.27 ± 0.76 mmol/L, P = 0.002), low-density lipoprotein cholesterol (1.71 ± 0.49 mmol/L vs. 1.08 ± 0.32 mmol/L, P < 0.001), and apolipoprotein B (0.49 ± 0.16 g/L vs. 0.42 ± 0.13 g/L, P = 0.004). Inflammatory markers interleukin-1β and tumor necrosis factor-α also decreased significantly in the Combination Therapy Group. Endothelial function improved, as indicated by flow-mediated dilation (5.01 ± 1.67% vs. 4.27 ± 1.32%, P = 0.003) and vascular activity range (4.20 ± 1.39 mm vs. 3.68 ± 1.22 mm, P = 0.017). The incidence of adverse cardiovascular events was lower in the Combination Therapy Group (3.95% vs. 14.67%, P = 0.023).
conclusionCompared to statin monotherapy, the combination of evolocumab with atorvastatin synergistically improved lipid control, reduced early inflammation, enhanced endothelial function, and decreased cardiovascular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.